Leyden Labs
Leiden, NL · 3 known investors
Leyden Labs develops nasal sprays containing antibodies that target respiratory viruses at the nasal mucosa to prevent initial infection and transmission. The company aims to provide broad protection against influenza, COVID-19, and future respiratory viruses for the general population.
BiotechHealthtechMedical Devices
Founders & leadership
KW
Koenraad WiedhaupFounder and Chief Executive Officer
RB
Ronald BrusFounder and Chief Growth Officer
JG
Jaap GoudsmitFounding Scientist and Senior Advisor
Investors · 3
In the news
- Leyden Labs Raises $40M in Funding | FirstWord PHARMAfirstwordpharma.com · 2026
- Leyden Labs Raises €40 Million To Advance Respiratory Virus Protection Platformpulse2.com · 2026
- Leyden Labs Secures €40M for Intranasal Antibodyallsci.com · 2026
- Leyden Labs secures €40 million to develop intranasal protection against influenza and coronaviruses | EU-Startupseu-startups.com · 2026
- Gates Foundation backs Leyden Labs' €40M raise: Can a nasal spray do what 80 years of flu vaccines couldn't — TFNtechfundingnews.com · 2026
- Globally Recognized Impact Investors Back Leyden Labs’ Mission to Transform Protection Against Respiratory Viruses with €40 Million Investmentbusinesswire.com · 2026